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USE OF L-CANAVANINE AS A 
CHEMOTHERAPEUTIC AGENT FOR THE 
TREATMENT OF PANCREATIC CANCER 
TECHNICAL FIELD 
The invention relates to a pharmaceutical composition 
comprising canavanine, and a method treatment of cancer, 
particularly pancreatic cancer, with L-canavanine. 
BACKGROUND 
More than 26,000 people die each year in our country 
from pancreatic adenocarcinoma (1, see numbered refer 
ences below). Death is the inevitable consequence to more 
than 90% of patients with this disease. It is the fourth most 
common cause of cancer death in men and the ?fth most 
common for women (2). Overall, it is the fourth most 
common carcinoma after those of the lung, colon and breast 
(3). The incidence of this disease is linear with age to sixty 
but its occurrence increases markedly in the seventh or 
eighth decade of life (4). There are several different histolo 
gies associated with cancer of the pancreas including small 
cell cancer, cystadenocarcinoma, islet cell tumors, lym 
phoma and carcinoid; however, 75-80% of the cases involve 
adenocarcinomas of ductal origin (5). The only de?nitive 
risk factor in pancreatic cancer is cigarette smoking. A 
typical smoker accepts up to four times the risk of a 
nonsmoker (6). 
Located in the upper abdomen in the retroperitoneum, the 
pancreas is associated intimately with many major structures 
including the portal vein, stomach, duodenum, common bile 
duct and the superior mesenteric artery. As the tumor grows, 
the patient’s symptoms result from tumor in?ltration of 
surrounding structure causing pain, nausea, vomiting, 
weight loss and jaundice. The latter condition presents 
symptoms in no more than one half of the patients. Once 
tumor in?ltration occurs other structures such as the portal 
vein become affected and this precludes curative resection~ 
ing of the pancreas. 
Effective treatment of pancreas cancer must achieve two 
dillicult goals: control of the primary tumor mass, both 
initially and subsequently, and treatment of the metastatic 
tumor cells. As a result of its insidious onset, the diagnosis 
of pancreas cancer is delayed frequently for several months. 
This delay has profound implications, since metastatic 
spread to the liver or lymph nodes has been observed at a 
time of diagnosis in 60% of patients, and this factor dimin 
ishes the prospect for long—term survival (7). Also, there are 
no known speci?c markers of carcinoma of the pancreas and 
it is asymptomatic in its early stage (8). 
Conventional Therapy for Pancreatic Cancer 
Currently, surgery is the primary and only curative 
therapy for pancreas cancer. However, only 15-25% of 
tumors are resectable at the time of diagnosis (9) and 
regrettably only 10-20% of patients resected will survive 
more than two years (10). With these less tan satisfactory 
surgical results, present day therapy has evolved in two 
directions: palliation of symptoms and aggressive multimo 
dality treatment regime’s which combines surgery with 
chemotherapy and radiation treatment. 
Palliative therapy has become a major thrust of current 
treatment. Initial relief of symptoms has relied on surgery 
with surgical bypass of gastric outlet obstruction (11) and 
operative bypass of biliary obstruction (12). Subsequent 
symptomatic treatment has centered around endoscopic 
placement of biliary stents to bypass tumors blocking the 
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biliary tract (13) and/or percutaneous placement of bypass 
conduits (l4). 
Aggressive multimodality therapy combining chemo 
therapy and radiation therapy which surgery has been the 
response of choice when surgery alone was not elfective. 
Radiation has been the cornerstone of therapy for unrespect 
able cancer of the pancreas and 5-?uorouracil (S-FU) che 
motherapy has been for an important adduct to radiation 
treatment in these patients (15). However, despite these 
valiant elforts, no patient survives ?ve years. 
A single, small randomized trial showed signi?cant ben 
e?t from combined radiation and chemotherapy given two 
years after operation (16). While this study was limited by 
an inadequate number of patients, none the less there was 
bene?t to patients receiving rnulti-modality treatment. 
Effective radiotherapy needs to maximize exposure of the 
affected tissues while sparing normal surrounding tissues. 
Interstitial therapy, where needles containing a radioactive 
source are embedded in the tumor, has become a valuable 
new approach. In this way, large doses of irradiation can be 
delivered locally while sparing the surrounding normal 
structures (17). Intraoperative radiotherapy, where the beam 
is placed directly onto the tumor during surgery while 
normal structures are moved safely away from the beam, is 
another specialized radiation technique. Again, this achieves 
e?’ective irradiation of the tumor while limiting exposure to 
surrounding structures. Despite the obvious advantage of 
approaches predicated upon local control of the irradiation, 
patient survival is not signi?cantly improved (18, 19). 
The foundation of chemotherapy for carcinoma for the 
pancreas has employed 5-FU(20). Here too, the prognosis is 
bleak; no better than 10-15% of patients treated with 5-FU 
will experience a signi?cant reduction in tumor size; overall 
survival rates are not improved. The addition of other 
chemotherapeutic agents such as cis~platin or adriarnycin 
has not dramatically improved disease management (20). 
For this reason, attempts to augment the intrinsic activity of 
S-FU have been undertaken. On one approach, 5-FU is 
converted to 4-?uorodeoxyuridine monophosphate 
(FdUMP) which binds covalently to thyrnidylate synthase 
(EC 2.1.1.45). This competitive inhibitor disrupts DNA 
replication by curtailing deoxyuridine monophosphate 
anabolism to deoxythyrnidine. 
Reduced folates such as leucovorin are a necessary cofac 
tor for FdUMP binding to thymidylate synthase (21). Cancer 
cells depauperate in reduced folate are resistant to S-FU 
chemotherapy but that resistance can be circumvented by 
providing exogenous reduced folate (22). While 5-PU plus 
leucovorin relative to 5-FU alone has proven e?icacious in 
treating colon cancer, patients with pancreas cancer received 
no bene?t by providing these two drugs in combination (23). 
S-Fluorouracil can also be converted to S-?uorouridine 
monophosphate which can be incorporated into mRNA 
thereby a?ecting protein translation. N-N-(phosphonacetyly 
L-aspartic acid (PALA) inhibits the transformation of aspar 
tic acid to orotidine monophosphate which is converted 
subsequently to uridine monophosphate. The use of PALA 
provides a means of depleting essential uridine monophos~ 
phate. In the absence of uridine monophosphate, ?uorouri 
dine monophosphate is incorporated preferentially into 
mRNA which promotes cell death. Preliminary data from 
experiments employing high dose (2,600 mg/m2) 5-FU after 
pretreatment with PALA have been promising as signi?cant 
tumor reduction has been noted in 5 of 6 patients (24). 
However, subsequent phase II data have been less positive 
(25) with only one patient in 29 achieving any bene?t. 
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While new experimental efforts in treating pancreas can 
cer have been initiated, their limited success emphasizes the 
need for radically new approaches in the management of this 
devastating disease. The present invention provides an addi 
tional alternative for the treatment of cancers, particularly 
pancreatic cancer by providing for a pharmaceutical com 
position comprising canavanine, and a method treatment of 
cancer, particularly pancreatic cancer with canavanine. 
DISCLOSURE OF THE INVENTION 
The present invention provides a method of treating 
pancreatic cancer by administering a pharrnaceutically 
effective amount of a composition comprising L-canavanine 
to a patient with pancreatic cancer. 
The invention also provides a pharmaceutical composi 
tion comprising a pharrnaceutically effective amount of a 
composition comprising L~canavanine. 
In an alternative embodiment the invention provides 
pharmaceutical composition comprising canavanine and 
5-?uorouracil. 
In still another embodiment the invention provides a 
pharmaceutical composition comprising canavanine and a 
compound selected from the group consisting of (S)-2 
aminoethyl-L-cysteine, L-2-azetidine carboxylic acid, L-se 
lenomethionine, L-3-[N-hydroxy-4-oxypyridyl]-2-arnino 
propionic acid and mixtures thereof. 
The above and other objects of the invention will become 
readily apparent to those of skill in the relevant art from the 
following detailed description and ?gures, wherein only the 
preferred embodiments of the invention are shown and 
described, simply by way of illustration of the best mode of 
carrying out the invention. As is readily recognized the 
invention is capable of modi?cations within the skill of the 
relevant art without departing from the spirit and scope of 
the invention. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 shows electrophoretic evidence of structural 
change caused by canavanine. Vitellogenin was examined 
by gradient polyacrylarnide electrophoresis as described 
elsewhere. 
FIG. 2 shows tumor growth in male Fischer rats following 
administration of canavanine, 2.0 (closed rectangle) or 3.0 
(closed circle) g/kg for 9 days. Control animals (closed 
triangle) receive 0.95 received 0.95 (w/v) NaCl. The stan 
dard error bar was omitted if within the area occupied by the 
data point, n=5 S.E.M. 
FIG. 3 shows tumor growth in male Fischer rats following 
5 daily so injections of 35 mg/kg S-FU (closed circle) 2.0 
g/kg canavanine (closed square), 1.0 g/kg canavanine (open 
triangle), 35 mg kg 5-FU plus 2.0 g/kg canavanine (open 
circle) or 35 mg/kg 5-FU plus 1.0 g/kg canavanine (open 
square). Control animals (closed triangle) received 0.95 
(w/v) NaCl. The S.E. bar was omitted if it fell within the area 
occupied by the data point, n:5 S.E.M. 
FIG. 4 shows MIA-PaCa-l cells were exposed to the 
indicated level of canavanine for 3 days in Dulbecco’s 
modi?ed media containing 0.4 mM arginine. Each point 
represents the means from an experiments. The standard 
error bar was omitted when it fell within the area occupied 
by the data point. 
FIG. 5 shows MIA~PaCa~1 cells were exposed to various 
amounts of canavanine with the indicated level of arginine 
to generate this family of curves. 
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FIG. 6A and 6B show Mice tumor volume (cm3) of 
control mice (A) and canavanine-treated mice (B). Canava 
nine-treated animals were injected daily with 4 g/Kg of drug 
in sterile saline, control animals receive 0.9% (w/v) NaCl. 
DESCRIPTION OF THE INVENTION 
The invention provides a pharmaceutical composition 
comprising canavanine, and a method treatment of cancer, 
particularly pancreatic cancer with canavanine. A depiction 
of the canavanine molecule appears below. 
In addition to the amino acids which are the building 
blocks of proteins, living systems also produce about 750 
nonprotein amino acids (26). These compounds possess a 
rich structural diversity and often elicit deleterious biologi 
cal effects in viruses and all living systems (27), L-Cana 
vanine, the L-2-amino-4-(guanidinoxy) butyric acid struc 
tural analog of L-arginine, is such a higher plant toxicant. 
Produced and stored by leguminous plants, canavanine is 
part of their chemical defense, where it functions as a barrier 
against a wide array of insects and other pests (28, 29). 
Biochemical Basis for Canavanine’s Antimetabolic Proper 
ties 
Studies with larvae of the tobacco horn worm, Manduca 
sexta, reveal that canavanine is an effective substrate for 
arginyl-tRNA synthetase. This canavanine-sensitive insect 
replaces on average at least one of three arginyl residues 
with canavanine in the de novo synthesized proteins of the 
hemolymph and body wall (30). 
Vitellin, an essential egg protein, is constructed by the 
gravid migratory locust, Locusta migratoria migratorioides 
[Orthoplera] from amino acids released by degradation of 
Vitellogenin (31). Administration of canavanine to the 
female locust produces a canavanyl Vitellogenin in which 18 
of the nearly 200 arginine residues are replaced by canava 
nine (31); thus, canavanine occurs about once every 225 
amino acids. In spite of this paucity in canavanine content, 
it elicits a profound alteration in‘vitellogenin structure best 
observed by electrophoretic analysis (FIG. 1). 
Other chemical, physical, biochemical, and immunologi 
cal tests con?rm the dramatic change in the three dimen 
sional conformation resulting from canavanine assimilation 
into this protein (31). 
In response to microbial infection or mechanical injury, 
larvae of the meat-eating ?y, Phormia terranovae, generate 
a group of antibacterial proteins known trivially as the 
diptericins. If canavanine is included at the time of mechani 
cal injury, it is incorporated into newly produced diptericins 
(32). Analysis of the diptericin activity of arginine- or 
canavanine-treated larvae reveals a nearly total loss of 
detectable biological activity for 3 of the 4 protective 
proteins-only diptericin A displays biological activity. Thus, 
canavanine incorporation into these protective proteins in 
place of arginine curtails severely their biological activity. 
Manduca sexta larvae respond to injected fragments of 
the cell wall of Micrococcus lutea by producing lysozyme 
(EC 3.2.1.17), a protein which cleaves the mucopolysaccha 
ride framework of the cell wall. Administration of 1 mg 
canavanine g-1 fresh larval weight at the time of bacterial 
challenge generates canavanyl lysozyme with a ratio of 
canavanine to arginine of l:3.8i0.2(33). Canavanyl 
lysozyme exhibits a 50% loss of catalytic activity (33). 
These insectan studies support out contention that the anti 
metabolic etfects of canavanine re?ects its incorporation 
into newly synthesized proteins which alters essential con 
formation and produces dysfunctional proteins. 
5,552,440 
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Canavanine may be produced by isolated the amino acid 
from jack beans by the method of Kitagawa, Tokiyama, J. 
Biochem., (Tokyo) 11, 265 (1929) incorporated herein by 
reference in its entirety. See also Nyberg et al., J. Am. Chem. 
Soc., 79, 1222 (1957); Frankel et al., J. Am Chem. Soc., 
3127 (1963); and Yamada et al., Agr., Biol. Chem., 37, 2201 
(1973) for additional methods of synthesis of canavanine, 
also incorporated herein by reference. 
Evaluation of Canavanine’s Antineoplastic Activity 
Canavanine‘s ability to disrupt the growth of rapidly 
dividing and growing larval cells led to whole animal studies 
of its antineoplastic activity. The inventors found that cana 
vanine may be incorporated into key protein(s) unique to the 
cancer cell and that these structurally aberrant proteins, 
critical to the growth and proliferation of the cancer cell, 
may be dysfunctional. 
EXAMPLE 1 
Employing a solid rat colonic carcinoma in Fischer F433 
rats, it was demonstrated that canavanine possesses appre 
ciable antineoplastic activity. For example, administration of 
canavanine at a 3.0 g/kg dosing regimen for 5 consecutive 
days results in a 22% loss in tumor volume, while 9 days of 
daily dosing elicits a 60% diminution of the tumor (34). 
However, canavanine’s is cumulatively toxic and can 
result in a weight loss of 19% in animals dosed with 3.0 g/kg 
canavanine for 5 days (34). Additional experimentation 
established unequivocally that the observed body weight 
loss is not responsible for canavanine’s antitumor e?ects 
(34). 
EXAMPLE 2 
Initial experimental efforts have been extended to deter 
mine if canavanine’s e?icacy as an anticancer agent is 
increased in combination with S-?uorouracil (S-FU). Pro~ 
viding canavanine at 1.0 g/kg or 2.0 g/kg daily for 5 
consecutive days with 5-FU increases signi?cantly the anti 
tumor activity of either drug alone (see FIG. 2). Body weight 
loss experienced by canavanine-treated animals increases in 
those animals given both drugs. These studies evidence that 
combination therapy o?fers a viable means of improving 
canavanine’s intrinsic efficacy. 
In order to improve canavanine’s potential as a chemo 
therapeutic agent, a number of canavanine derivatives were 
evaluated for enhanced antitumor ef?cacy and diminished 
growth-inhibiting activity. 
Enzyme activity studies conducted, reveal a number of 
other nonprotein amino acids whose assimilation into pro 
teins disrupts normal catalytic activity. Some natural prod 
ucts such a (S)~2—aminoethyl-L-cysteine, L~2~azetidine car 
boxylic acid, L~selenomethionine, and L-3-[N~hydroxy-4 
oxypyridyl]-2- aminopropionic acid or mixtures thereof are 
not only very active but also interact with canavanine to 
signi?cantly amplify canavanine-mediated disruption of 
protein function (35). 
Thus, there are a number of nonprotein amino acids 
beside canavanine able to substitute for their protein amino 
acid counterpart to generate dysfunctional proteins. These 
natural products often possess signi?cant antitumor poten~ 
tial alone, in combination with canavanine, and with other 
therapeutic drugs. 
The ability to assault the local cancer cell and even its 
metastatic offspring simultaneously with an array of non 
protein amino acid derivatives o?ers a weapon of consid 
erable potential value. 
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Canavanine’s Efficacy against Pancreatic Tumor 
Analysis of L-[guanidinoxy-MC] canavanine uptake into 
the protein of the major organs of the rat disclosed the 
highest radiolabeling in pancreatic proteins (36). These 
proteins had 10 times the amount found in liver, muscle or 
brain samples. The ef?cient incorporation of radiolabeled 
canavanine into pancreatic proteins coupled with its dem 
onstrated ability to create dysfunctional proteins prompted 
evaluation not only of canavanine but more importantly its 
derivatives as chemotherapeutic agents for human pancreas 
cancer. 
A basic understanding of the biochemical basis for cana 
vanine’s antimetabolic properties has emerged over the past 
?ve years and these efforts have permitted development of 
a sound rationale for derivative synthesis. Chemical syn 
thetic efforts, detailed herein, hold the promise of providing 
drugs with markedly enhanced e?‘icacy and permit their 
administration at signi?cantly lower dose levels than those 
required by canavanine. It has been unequivocally estab 
lished that a l g kg-1 dose of canavanine has no adverse 
effect on body weight nor on other discernible parameters of 
the rat. 
A chemotherapeutic strategy predicated upon controlling 
cancer cell growth through the formation of structurally 
aberrant, dysfunctional proteins has been developed. Such 
macromolecules deny the cancer cell essential metabolites, 
undermine regulatory and other cellular control elements 
and pervasively disrupt critical cellular growth-related pro 
cesses. Current treatment practices have not enjoyed sub 
stantial success and a radical new approach is justi?ed. The 
approach of the invention is one with a strong biochemical 
foundation that provides a sound rationale for the develop 
ment of new derivatives for use as chemotherapeutic agents. 
Most importantly, canavanine’s mode of actions is snot 
directed at DNA replication, events that occur prior to 
transcription of the message, nor at message translation. 
The present strategy for developing an effective chemo 
therapeutic agent does not focus on nucleic acid metabolism 
but rather at the level of protein function. 
Evaluation of Drug Ef?cacy 
A number of cell lines derived from pancreatic ductal 
adenocarcinoma have been established, including CFPAC-l 
(ATCC CRL 1918), PANC-l (ATCC CRL 1469), MIA 
PaCa- 1, and MIA-PaCa-2 (ATCC CRL 1420). MIA-PaCa2 
is highly tumorigenic, has lost the ability to be growth 
regulated, and is derived from metastatic cells. CFPAC- 1, 
which is derived from a primary tumor line, is the faster 
growing cell line and is preferable for whole animal studies. 
The availability of each of these lines from the American 
Type Culture Collection, 12301 Parklawn Drive, Rockville, 
Md., U.S.A., insures an effective means for initial screening 
of newly synthesized derivatives both alone and in combi 
nation with other developed compounds as well as with 
drugs employed presently inhuman chemotherapy. The most 
promising candidates are employed in whole animal evalu 
ation involving nude mice. 
This invention permits an effective transition from labo 
ratory ?ndings and evaluations to their bene?cial employ 
ment in alleviating the human suffering associated with this 
dreadful disease. 
EXAMPLE 3 
Antitumor Effect of Canavanine in the Male Fischer Rat 
The marked antitumor effect of L-canavanine was dem 
onstrated initially by our research group in studies on a solid, 
colonic carcinoma in male Fischer 344 rats. Administration 
of 3 g/kg canavanine sc reproducibly prevented tumor 
growth during 5 or 9 consecutive treatment days. In fact, the 
?nal fresh tumor weight was typically 10% less than the 
weight of the initial tumor (34) (FIG. 2). 
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To enhance canavanine’s antineoplastic activity, it was 
tested in combination with 5-FU (FIG. 3). Providing cana 
vanine at 1.0 g/kg or 2.0 g/kg daily for 5 consecutive days 
with 5-FU increased signi?cantly the antitumor activity of 
either drug alone. This whole animal study was of consid 
erable importance because it demonstrated that combination 
therapy offers a viable mean of improving canavanine’s 
intrinsic e?icacy and supports our contention that canava 
nine and its derivatives in conjunction with S-FU may offer 
an effective chemotherapeutic strategy. Alternatively, cana 
vanine therapy may be combined with radiotherapy. 
EXAMPLE 4 
The Effect of Canavanine on MIA~PaCa~I Cells. 
Work has been performed to evaluate the e?ect of cana 
vanine on MIA-PaCa-l cells. Cell survival was determined 
by the ability of viable cells grown on Dulbecco’s modi?ed 
medium to reduce tetrazolium dye to a colored forrnazan 
product. The experiment depicted in FIG. 4 discloses dra 
matically the potent e?icacy of canavanine against these 
cells. 
That the antitumor potential of canavanine is related 
directly to the competing arginine concentration is depicted 
in FIG. 5. This ?nding is of great importance because it 
reveals that canavanine is functioning as an effective argi 
nine antagonist. This point is seminal to our contention that 
the antitumor e?ect of canavanine is related to its compe 
tition with arginine for arginyl-tRNA synthetase. 
EXAMPLE 5 
The Antineoplastic E?'ect of Canavanine in the Nude Mouse 
Experimental effects with athymic nude mice were con 
ducted with 6 treated and control mice. The palpable 
CFPAC-l-derived tumors grew slowly but after 28 days 
appreciable tumor growth had occurred in all experimental 
animals (FIG. 6A). By contrast, the CPFAC-l-derived 
tumors exhibited little growth in canavaninetreated animals 
(FIG. 6B). In 2 of the 7 experimental animals, a precipitous 
decline in tumor volume was observed during the ?rst 
treatment week. These exciting experimental results add 
further support to the fact that canavanine and its derivatives 
possess considerable potential for the treatment of human 
pancreatic carcinoma. 
Further, the compounds of the present invention are useful 
in pharmaceutical compositions for systemic administration 
to humans and animals in unit dosage forms, such as tablets, 
capsules, pills, powders, granules, suppositories, sterile 
parenteral solutions or suspensions, sterile non-parenteral 
solutions or suspensions oral solutions or suspensions, oil in 
water or water in oil emulsions and the like, containing 
suitable quantities of an active ingredient. 
For oral administration either solid or ?uid unit dosage 
forms can be prepared. The compounds are useful in phar 
maceutical compositions (wt %) of the active ingredient 
with a carrier or vehicle in the composition in about 0.01 to 
99% and preferably about 5 to 15%. 
Either ?uid or solid unit dosage forms can be readily 
prepared for oral administration. For example, the com 
pounds can be mixed with conventional ingredients such as 
dicalciumphosphate, magnesium aluminum silicate, magne 
sium stearate, calcium sulfate, starch, talc, lactose, acacia, 
methyl cellulose and functionally similar materials as phar 
maceutical excipients or caniers. A sustained release for 
mulation may optionally be used. Capsules may be formu 
lated by mixing the compound with a pharmaceutical diluent 
which is inert and inserting this mixture into a hard gelatin 
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capsule having the appropriate size. If soft capsules are 
desired a slurry of the compound with an acceptable veg 
etable, light petroleum, or other inert oil can be encapsulated 
by machine into a gelatin capsule. 
Suspensions, syrups and elixirs may be used for oral 
administration of ?uid unit dosage forms. A ?uid preparation 
including oil may be used for oil soluble forms. A vegetable 
oil such as corn oil, peanut oil or safflower oil, for example, 
together with ?avoring agents, sweeteners and any preser 
vatives produces an acceptable ?uid preparation. A surfac 
tant may be added to water to form a syrup for ?uid unit 
dosages. Hydro-alcoholic pharmaceutical preparations may 
be used having an acceptable sweetener such as sugar, 
saccharine or a biological sweetener and a ?avoring agent in 
the form of an elixir. 
Pharmaceutical compositions for parenteral administra 
tion can also be obtained using techniques standard in the art 
as set forth in Remington ’s Pharmaceutical Sciences, 18th 
Ed., 1989, Mack Publishing Company, incorporated herein 
by reference it its entirety. 
Accordingly, compositions suitable for administration are 
particularly included within the invention. Parenteral solu~ 
tions or suspensions may be administered. If desired, a more 
concentrated slow release form may be administered. 
Accordingly, incorporation of the active compounds in a 
slow release matrix may be implemented for administering 
transderrnally. The compounds may preferably be adminis 
tered at about 1 to 20% of the composition and more 
preferably about 5 to 15% wt % of the active ingredient in 
the vehicle or carrier. 
The above and other drugs can be present in the reservoir 
alone or in combination form with pharmaceutical carriers. 
The pharmaceutical carriers acceptable for the purpose of 
this invention are the art known carriers that do not 
adversely aifect the drug, the host, or the material compris 
ing the drug delivery device. Suitable pharmaceutical car 
riers include sterile water; saline, dextrose; dextrose in water 
or saline; condensation products of castor oil and ethylene 
oxide combining about 30 to about 35 moles of ethylene 
oxide per mole of castor oil; liquid acid; lower alkanols; oils 
such as corn oil; peanut oil, sesame oil and the like, with 
emulsi?ers such as mono- or di-glyceride of a fatty acid, or 
a phosphatide, e.g., lecithin, and the like; glycols; polyalky~ 
lene glycols; aqueous media in the presence of a suspending 
agent, for example, sodium carboxymethylcellulose; sodium 
alginate; poly(vinylpyrolidone); and the like, alone, or with 
suitable dispensing agents such as lecithin; polyoxyethylene 
stearate; and the like. The carrier may also contain adjuvants 
such as preserving stabilizing, wetting, emulsifying agents 
and the like together with the penetration enhancer of this 
invention. 
The effective dosage for mammals may vary due to such 
factors as age, weight activity level or condition of the 
subject being treated. Typically, an effective dosage of a 
compound according to the present invention is about 0.1 to 
50 mg per kilogram of the subject’ 5 weight administered per 
day. Preferably about 25 to 50 mg per kilogram body weight 
is administered a day. The required dose is less when 
administered parenterally, preferably about 25-30 mg per 
kilogram of body weight per day may be administered 
intramuscularly. 
The purpose of the above description and examples is to 
illustrate some embodiments of the present invention with 
out implying any limitation. It will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made to the composition and method of the present 
invention without departing from the spirit or scope of the 
5,552,440 
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invention. All patents and publications cited herein are 
incorporated by reference in their entireties. 
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We claim: 
1. A method of treating pancreatic cancer comprising the 
steps of administering a pharmaceutically effective amount 
of a composition comprising canavanine to a patient with 
pancreatic cancer. 
2. A method of treating pancreatic cancer according to 
claim 1 wherein said canavanine is L-canavanine. 
3. A method of treating pancreatic cancer according to 
claim 1 wherein said composition further comprises 5-?u0 
rouracil. 
4. A method of treating pancreatic cancer according to 
claim 1, wherein said composition further comprises a 
compound selected from the group consisting of (S)-2 
aminoethyl-L-cysteine, L-2-azetidine carboxylic acid, L-se 
lenomethionine, L-3-[N-hydroxy-4-oxypyridyl]-2-amino 
propionic acid and mixtures thereof. 
5. A method of treating pancreatic cancer according to 
claim 1, wherein said pharmaceutically effective amount is 
about 25 to 50 mg per kilogram body weight a day. 
6. A pharmaceutical composition consisting essentially of 
canavanine and 5-?uorouraci1. 
7. A pharmaceutical composition consisting essentially of 
canavanine and a compound selected from the group con 
sisting of (S)-2-arninoethyl-L-cysteine, L-2-azetidine car~ 
boxylic acid, L-selenomethionine, L-3-[N-hydroxy-4-oxy 
pyridyl]-2-aminopropionic acid and mixtures thereof. 
* * * * * 
